NCT04952272View on ClinicalTrials.gov

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2036

Conditions
Lung CancerHepatocellular CarcinomaSolid Tumor
Interventions
COMBINATION_PRODUCT

CpG-ODN

CAR-T cells secreting scFv against OX40

Trial Locations (1)

510260

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
collaborator

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

OTHER

lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER